| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Do | Cibus-Aktie fällt nach Preisfestsetzung für 20-Millionen-Dollar-Kapitalerhöhung | 2 | Investing.com Deutsch | ||
| Do | Cibus prices public offering of 13.3 million shares at $1.50 each | 2 | Investing.com | ||
| Do | Cibus legt Preis für Aktienemission fest: 13,3 Millionen Aktien zu 1,50 US-Dollar | 1 | Investing.com Deutsch | ||
| Do | Cibus, Inc.: Cibus, Inc. Announces Pricing of $20.0 Million Public Offering of Class A Common Stock | 1 | GlobeNewswire (USA) | ||
| CIBUS Aktie jetzt für 0€ handeln | |||||
| Mi | Cibus announces planned underwritten public offering of Class A shares; shares down | 2 | Seeking Alpha | ||
| Mi | Cibus, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| Mi | Cibus, Inc.: Cibus, Inc. Announces Proposed Public Offering of Class A Common Stock | 1 | GlobeNewswire (USA) | ||
| 06.01. | Cibus, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 11.12.25 | Cibus, Inc.: Cibus Welcomes the Positive Conclusion of Trilogue Negotiations on New Genomic Techniques Legislation Between the European Parliament and Council | 273 | GlobeNewswire (Europe) | Political agreement on New Genomic Techniques (NGTs), including gene editing, advances a science-based path for plant breeding innovation and supports Cibus' plans to bring improved traits to European... ► Artikel lesen | |
| 25.11.25 | Superannuation giant Cbus hit with penalty for mishandling insurance claims | 3 | ABC online | ||
| 14.11.25 | Cibus outlines $200M annual rice royalty target while advancing global commercialization strategy | 3 | Seeking Alpha | ||
| 13.11.25 | Cibus, Inc. - 10-Q, Quarterly Report | - | SEC Filings | ||
| 11.11.25 | Cibus names Farmland LP founder Craig Wichner to board of directors | 4 | Investing.com | ||
| 11.11.25 | Cibus, Inc.: Cibus Announces the Election of Craig Wichner to Board of Directors | 1 | GlobeNewswire (USA) | ||
| 10.11.25 | Cibus beruft Farmland-LP-Gründer Craig Wichner in den Verwaltungsrat | 2 | Investing.com Deutsch | ||
| 10.11.25 | Cibus, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 16.10.25 | Cibus, Inc.: Cibus and AgVaya Collaborate to Introduce Indian Rice Growers to New Solutions to Scale Crop Productivity Through Advanced Gene Editing | 2 | GlobeNewswire (USA) | ||
| 15.10.25 | What's Driving Cibus Inc.'s Pre-Market Surge Amid Trump's China Trade Warning? | 1 | Benzinga.com | ||
| 08.10.25 | The ESG Phenomenon: Cibus Capital, Australia | 1 | WealthBriefing | ||
| 02.10.25 | Cibus, Inc.: Cibus Announces Positive Field Trial Results for Second-Generation Herbicide Tolerance (HT2) Edited Canola | 191 | GlobeNewswire (Europe) | Field testing confirms efficacy of HT2 trait in Canola under real-world conditions HT2 trait will be offered to potential seed licensing partners for introduction into commercial Canola seed products... ► Artikel lesen |
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 95,80 | -0,21 % | Pharma- und Biotech-Aktien 2026: Bayer und BioNTech geben Gas, Bioxyne vor Durchbruch? | ||
| EVOTEC | 6,218 | -0,80 % | Puma-Übernahme wird konkreter! Als nächstes Evotec und Silver Viper Aktien kaufen? | Schon länger gibt es Übernahmespekulationen rund um Puma. Jetzt hat sich Anta 29 % am deutschen Sportartikelkonzern gesichert. Dafür zahlen die Chinesen 35 EUR je Aktie. An der Börse hält sich die Euphorie... ► Artikel lesen | |
| MODERNA | 36,760 | -1,17 % | Moderna, Inc.: Dr. David Berman to Join Moderna as Chief Development Officer | CAMBRIDGE, MASSACHUSETTS / ACCESS Newswire / January 30, 2026 / Moderna, Inc. (NASDAQ:MRNA) today announced that David Berman, M.D., Ph.D. has been appointed as the Company's Chief Development Officer... ► Artikel lesen | |
| NOVAVAX | 7,437 | -0,34 % | NOVAVAX INC: Schwäche mit Signalwirkung | ||
| ILLUMINA | 122,04 | -0,08 % | Illumina, Inc.: Illumina completes acquisition of SomaLogic from Standard BioTools Inc. | Deeply expands leadership in proteomics and multiomicsCombined capabilities bring high scalability, flexibility, and affordability into protein analysis Combination leverages SomaScan with Illumina's... ► Artikel lesen | |
| PALATIN TECHNOLOGIES | 14,905 | -1,29 % | Palatin Technologies, Inc.: Palatin Reports First Quarter Fiscal Year 2026 Financial Results and Provides Corporate Update | Significant progress on multiple fronts - obesity pipeline advancing towards the clinic, out-licensing collaboration, strengthened balance sheet, and reinstatement... ► Artikel lesen | |
| BRAIN BIOTECH | 2,400 | +3,00 % | Brain Biotech: Kursziel der Aktie wird gestutzt | Die Analysten der Deutschen Bank bezeichnen die jüngsten Zahlen von Brain Biotech als Enttäuschung. 2024/2025 sinkt der Umsatz von 54,6 Millionen Euro auf 49,6 Millionen Euro. Für das neue Geschäftsjahr... ► Artikel lesen | |
| EDITAS MEDICINE | 1,645 | -1,26 % | Editas Medicine, Inc.: Editas Medicine Nominates EDIT-401, an LDLR-Targeted Medicine, as Lead In Vivo Development Candidate | EDIT-401 achieved ~90% mean LDL-C reduction with single dose in non-human primates EDIT-401 on track for human proof-of-concept data by end of 2026 Strong cash position with operational runway into... ► Artikel lesen | |
| TREVENA | 2,280 | -40,00 % | Hollywood Changemaker Oliver Trevena Joins Little Kitchen Academy as Investor | LOS ANGELES, CA / ACCESS Newswire / August 21, 2025 / Little Kitchen Academy (LKA), the premier Montessori-inspired cooking academy for children and teens ages 3-18, is proud to announce that Oliver... ► Artikel lesen | |
| BIOCRYST PHARMACEUTICALS | 5,586 | +0,68 % | BioCryst Pharmaceuticals, Inc.: BioCryst Completes Acquisition of Astria Therapeutics, Expanding Leadership in Hereditary Angioedema | RESEARCH TRIANGLE PARK, N.C., Jan. 23, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that it has completed its acquisition of Astria Therapeutics, Inc., initially... ► Artikel lesen | |
| IBIO | 1,810 | +1,12 % | iBio, Inc.: iBio Reports Q1 Fiscal Year 2026 Financial Results and Provides Corporate Update | Strengthened cash position and extended runway into the fourth quarter of fiscal year 2027 after closing underwritten public offering with up to potentially $100 million of total gross proceeds Presented... ► Artikel lesen | |
| ATAIBECKLEY | 3,765 | -2,33 % | Psychodelika-Aktien: Sind Bioxyne, Compass Pathways und Atai "the next big thing"? | ||
| TME PHARMA | 0,060 | 0,00 % | TME Pharma NV: TME Pharma provides update on its activities | TME Pharma provides update on its activities Berlin, Germany, January 5, 2025, 08.00 CET - TME Pharma N.V. (Euronext Growth Paris: ALTME), a clinical-stage biotechnology company specializing in the... ► Artikel lesen | |
| PHIO PHARMACEUTICALS | 1,010 | -0,98 % | Phio Pharmaceuticals Corp.: Phio Pharmaceuticals Announces Participation in Third Annual DealFlow Discovery Conference | King of Prussia, Pennsylvania--(Newsfile Corp. - January 26, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its... ► Artikel lesen | |
| CELLECTIS | 3,240 | +0,93 % | Cellectis Announces 2026 Strategy and Catalysts | NEW YORK, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Cellectis (the "Company") (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene editing platform to... ► Artikel lesen |